SR-9009

SR‑9009, also known as Stenabolic, is a synthetic small molecule developed as an agonist of the nuclear receptors REV‑ERBα and REV‑ERBβ. It was originally created by Thomas Burris at the Scripps Research Institute for research purposes. The drug modulates circadian rhythm and metabolism by increasing the constitutive repression of genes regulated by REV‑ERBs. In animal studies, activation of these receptors with SR‑9009 led to increased mitochondrial content in skeletal muscle and improved exercise capacity. However, more recent research has shown that some effects of SR‑9009 are independent of REV‑ERBs, including impacts on cell proliferation and metabolism in certain cell types. There is no approved therapeutic use for humans; it is not approved for medical use anywhere globally and has not been tested in human clinical trials. It is marketed illicitly online as a performance enhancer or weight loss agent but is banned by anti-doping agencies due to its potential for abuse[1][2][3][5].

Brand names

Stenabolic

Other names

ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate1-pyrrolidinecarboxylic acid, 3-[[(4-chlorophenyl)methyl][(5-nitrothiophen-2-yl)methyl]amino]methyl-, ethyl esterCAS#1379686-30-2